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Abstract
Background: In the last decades, the provision of pharmaceutical care by community pharmacists has developed
in OECD countries. These developments involved significant changes in professional practices and organization of
primary care. In France, they have recently been encouraged by a new legal framework and favored by an
increasing demand for health care (increase in the number of patients with chronic diseases) and reductions in
services being offered (reduction in the number of general practitioners and huge regional disparities).
Objectives: This study aimed to investigate final-year pharmacy students’ opinions on 1/expanding the scope of
pharmacists’ practices and 2/the potential barriers for the implementation of pharmaceutical care. We discussed
these in the light of the experiences of pharmacists in Quebec, and other countries in Europe (United Kingdom
and the Netherlands).
Methods: All final-year students in pharmaceutical studies, preparing to become community pharmacists, at the
University Paris-Descartes in Paris during 2010 (n = 146) were recruited. All of them were interviewed by means of
a questionnaire describing nine “professional” practices by pharmacists, arranged in four dimensions: (1) screening
and chronic disease management, (2) medication surveillance, (3) pharmacy-prescribed medication and (4)
participation in health care networks. Respondents were asked (1) how positively they view the extension of their
current practices, using a 5 point Likert scale and (2) their perception of potential professional, technical,
organizational and/or financial obstacles to developing these practices.
Results: 143 (97.9%) students completed the questionnaire. Most of practices studied received a greater than 80%
approval rating, although only a third of respondents were in favor of the sales of over-the-counter (OTC) drugs.
The most significant perceived barriers were working time, remuneration and organizational problems, specifically
the need to create a physical location for consultations to respect patients’ privacy within a pharmacy.
Conclusions: Despite remaining barriers to cross, this study showed that future French pharmacists were keen to
develop their role in patient care, beyond the traditional role of dispensing. However, the willingness of doctors
and patients to consent should be investigated and also rigorous studies to support or refute the positive impact
of pharmaceutical care on the quality of care should be carried out.
Background
Faced with increasing demand for health care and
reductions in services being offered, particularly by gen-
eral practitioners (GPs), questions are increasingly being
raised in various regions of France about the health care
principles of proximity, availability and access. To allevi-
ate these problems, a health-care reform law was
adopted in 2009 (known as the “Hôpital, Patients, Santé,
Territoires” or “HPST” law). Primary care is at the
forefront of this reform, and for the first time, a legisla-
tive framework is broadening the role of pharmacists in
providing these services. After being merely a dispenser
of medications (article R4235-48 of the Public Health
law), the pharmacist is now being assigned responsibil-
ities in front-line health care, health-care coordination,
screening and therapeutic education (article 38 of the
HPST law).
In 2009, there were 22,386 pharmacies in metropolitan
France and 53,460 practicing pharmacists, with an aver-
age of one pharmacy for every 2,849 inhabitants [1].
The geographical distribution of pharmacies in France is
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relatively homogeneous because the licensing of phar-
macies is regulated by demographic criteria, with one
pharmacy per 2,500 or 3,000 inhabitants according to
the size of the locality (law of September 11, 1941).
With these figures, France has one of the highest phar-
macy densities in Europe. The over-the-counter (OTC)
market in France is different from neighboring Eur-
opean countries. Drugs provided without prescription
account for only 17% of the volume of items sold in
pharmacies [2].
The challenge today is to understand the conditions
and consequences of a number of technical, organiza-
tional and social innovations. No scientific study has
examined this issue with respect to the pharmacists’
professional practices in France. One could hypothesize
that the pharmacist model, in the meaning used by
Hepler and Strand [3] as a dispenser of pharmaceutical
care, may become the practice in France as well. In any
case, the current discrepancies between the demand for
and supply of health care provide a context that is con-
ducive to this model, and the legal framework
encourages this trend. However, the opposite hypothesis
may also be valid; the redefinition of the pharmacist’s
profession [4] and professional, economic and/or organi-
zational boundaries together with normal resistance to
change may become obstacles to the implementation of
this reform [5].
The objective of the present study was to analyze the
opinions of final-year pharmacy students on expanding
the scope of pharmacists’ practices in France and
thereby assess the potential barriers to adopting new
practices.
Methods
Survey population
The survey population consisted of all final-year stu-
dents in pharmaceutical studies who were preparing to
become community pharmacists at the University of
Paris-Descartes in Paris during 2010 (n = 146). All of
these students were questioned at the end of their
6-month, final-year practical experience of working in a
community pharmacy. We took advantage of the fact
that these students were required to return to the uni-
versity between June 21 and 28 for an oral examination
to validate their practical experience. During this week,
after we obtained their oral consent, we administered a
printed questionnaire to all the students. These ques-
tionnaires were collected at the end of the examination.
Questionnaire
In France, the pharmacist’s mission already extends
beyond merely the sale of medications. They also pro-
vide advice to patients and sell OTC drugs without
medical prescriptions. However, their mission is far
from providing patient-centered services [6]. Drawing
on the HSPT law and experience in other countries
[7-9], we developed a questionnaire describing nine
practices of pharmacists. These are summarized in
Table 1 and are arranged in four dimensions: (1) screen-
ing and chronic disease management, (2) medication
surveillance, (3) pharmacy-prescribed medication and
(4) participation in health-care networks.
The respondents were asked two questions: (1) how
positively they view the extension of their current prac-
tices (using a 5-point Likert scale from “strongly favor-
able” to “strongly unfavorable”) and (2) their perception
of potential professional, technical, organizational and/
or financial obstacles to developing these practices.
For this latter variable, several response categories were
provided. Upon completion of the questionnaire, we col-
lected data on the respondents’ characteristics, such as
age, gender, motivation for selecting the community-
pharmacy option in their studies (four alternatives) and
the degree to which their practical experience working
in a community pharmacy reflected their expectations
(using a Likert scale with five choices from “completely”
to “not at all”).
Results
The questionnaire was completed by 143 of the 146 the
students (97.9%) enlisted. The three remaining students
left before the examination was completed and did not
complete the questionnaire.
Sample characteristics
The majority of the respondents were women (73.9%),
and the average age was 25.1 ± 1.6 years. These students
chose the community-pharmacy option in their studies
because of their desire for patient contact (46.1%), their
wish to create an enterprise (11.2%) or a combination of
these reasons (28.7%). Only 8.4% chose the community-
pharmacy option by default, and 5.6% did not know
how to answer this question. For the majority (79.2%),
their experience working in a community pharmacy met
their expectations “completely” or “almost completely,”
but 17.1% indicated “averagely” and 3.5% answered “lit-
tle” or “not at all.”
Opinions on expanding the scope of pharmacists’
practices
Figure 1 shows the respondents’ opinions on expanding
the scope of the pharmacist’s practices. Eight of the 9
practices studied received a greater than 80.0% approval
rating ("favorable” or “strongly favorable”). However,
only 34.3% had “favorable” or “strongly favorable” opi-
nions about expanding the sales of OTC drugs. We
should note that 14.7% felt “Strongly unfavorable” about
this practice.
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Obstacles to developing new practices
Figure 2 summarizes the potential obstacles to develop-
ing new pharmacists’ practices. Lack of time and appro-
priate remuneration constitute the major barriers to
developing the four practices under the “screening and
chronic disease management” heading. These items were
respectively checked by 77.0% and 61.2% of respondents
with respect to “pharmaceutical consultation” and by
75.2% and 51.8% for developing “therapeutic education.”
Also, organizational obstacles, specifically the need to
create a physical location for consultations to respect
patients’ privacy within a pharmacy, were seen by most
respondents (56.8%) as a brake on “pharmaceutical con-
sultation” and by more than a third (36.4%) as limiting
the development of “screening.” Finally, lack of training
and competition with doctors were considered to be
significant impediments to developing “pharmacists as
coordinators of care,” with 30.0% of the respondents
Table 1 Description of the nine pharmacists’ practices
Dimension 1: Screening and chronic disease management
The pharmaceutical consultation Individual interview in a confidential area to inform and counsel the patient by explaining the treatment, its
side effects, and drug interactions, and any follow-up to be adopted.
Therapeutic education Practical tools for the patient to acquire skills to manage their disease and its care and supervision in
partnership with health-care providers.
The pharmacist as a coordinator
of care
A protocol allowing the community pharmacist, chosen by the patient, to periodically renew chronic
treatments, adjust dosage (if necessary), and make medication-use reviews (side effects, observance, follow-up)
at a doctor’s request or with his consent.
Screening Offering screening procedures for certain ailments to patients using easily administered tests such as blood
pressure, expiratory flow rate, and blood-sugar levels.
Dimension 2: Medication surveillance
The electronic pharmaceutical
record (e-pr)
Making an electronic file for each patient containing all drugs dispensed to the patient during the last four
months for his or her own personal consumption, with or without medical prescription, in any pharmacy that is
equipped for such recording.
The pharmaceutical opinion A professional opinion, under the pharmacist’s authority, on the pharmaceutical appropriateness of one or a
series of treatments to be dispensed by the pharmacist. This is to be communicated on a standardized form to
the prescriber of the medication and/or to the patient when the pharmacist recommends a revision or to
justify his refusal to dispense a medication as prescribed.
Dimension 3: Pharmacy-prescribed medication
Prescription for minor ailments Dispensing certain medications without a medical prescription or advising patients to consult a doctor,
following appropriate questioning of the patient to determine the gravity of the symptoms of his or her
ailment.
Sales of over-the-counter drugs Direct public access to medications referred to as “pharmaceutical products” in specific, clearly identified
locations in very close proximity to where medications are dispensed, and providing the public with
information from respected health-care authorities relative to the appropriate use of these products.
Dimension 4: Participation in health-care networks
Pharmacotherapeutic
consultation groups
Group discussions with GPs and/or other specialists to discuss the clinical situation of patients for whom they
jointly provide care, such as in the framework of health-care networks.
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Figure 1 Final-year pharmacy students’ opinions on expanding the scope of the pharmacist’s practices (%).
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checking these two items. Competition with doctors was
cited by 30.0% as an obstacle for “screening.”
With respect to the “medication surveillance” dimen-
sion, half of the respondents checked technical obsta-
cles, specifically those involving computer hardware and
the problem of sharing information between health-care
professionals. These were cited by 45.5% as factors limit-
ing “electronic pharmaceutical record” (e-pr) develop-
ment and by 50.7% as factors limiting “pharmaceutical
opinion.” Time was also mentioned as a factor con-
straining e-pr development by a third of the respondents
(33.6%), and by more than 50.0% (57.9%) as limiting
“pharmaceutical opinion,” whereas remuneration was
infrequently selected as a limiting factor. It is particu-
larly striking that nearly two-thirds of the respondents
(65.7%) considered patient reticence as a potential
obstacle to e-pr development.
As for the “pharmacy-prescribed medication” dimen-
sion for minor ailments, in addition to the lack of remu-
neration, which was considered by nearly half (46.5%) of
the respondents as a barrier, we also found problems
with competing with doctors (40.8%) and, to a lesser
extent, lack of training (26.8%). Less than one-fifth of
the respondents (16.9%) mentioned lack of time for this
dimension. For “selling OTC medications,” the notable
finding was the high percentage (72.1%) who perceived
the risk of pharmacies becoming “drugstores” as an
obstacle to its development. Added to this were organi-
zational problems, specifically the space available for
these items in pharmacies (33.6% of respondents).
Finally, for “participation in health-care networks,” time
and (to a lesser degree) remuneration were seen as the
principal obstacles (75.0% and 37.1%, respectively).
Discussion
Pharmaceutical care
The concept of pharmaceutical care originated in an
article by Hepler and Strand [3]. Although there are sev-
eral definitions of this concept, most agree that a phar-
macist’s commitment to the patient is to attain the
patient’s health objectives. This concept has become
widely used in North America, particularly in Quebec,
but it has received less recognition in Europe [10], with
the exception of the United Kingdom and the Nether-
lands [8]. The pharmacists’ practices considered in the
present study are integrated into the concept of pharma-
ceutical care that is defined by the Ordre des Pharma-
ciens du Québec (The College of Pharmacists in
Quebec) as: “all the acts and services that the pharma-
cist is required to provide to patients, in order to
improve the quality of their lives by attaining the phar-
macotherapeutic objectives of prevention, cure or the
provision of palliative care.” [11]
Screening and chronic disease management
In Quebec, community pharmacists can, during a pri-
vate pharmaceutical consultation with a patient, provide
the following: develop a pharmaceutical care plan and
the objectives to be attained; write a pharmaceutical opi-
nion with suggestions to the patient’s doctor to revise
the patient’s treatment; conduct simple tests in follow-
up treatment, such as blood pressure; take the time to
explain the treatment and the ailments; and listen to
what the patient has to say [12,13]. The pharmacist can
also participate in therapeutic education projects by
showing patients how to modify their lifestyle to reduce
their symptoms and improve their short-, medium- and
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long-term health status [14]. New approaches that give
pharmacists the right to write out prescriptions are
emerging elsewhere, such as in the United States and
the United Kingdom, through establishing a protocol
between the doctor, the pharmacist and the patient,
defining the procedures and responsibilities of each per-
son and developing the health-care project to be
adopted. Collaborative drug-therapy management is
practiced throughout the United States and is officially
recognized in 25 states and by the federal government
(Armed Forces and Veterans Affairs) [15]. In the United
Kingdom, following a public consultation and under
advice from the Committee on Safety of Medicines and
the Medicines Commission, Ministers in 2003 agreed to
the implementation of supplementary prescribing [9].
The procedures can be followed to different degrees,
such as ranging from the initiation of treatment through
to modifying and/or renewing the medication therapy.
In France, the pharmacist’s involvement in providing
care for patients with chronic ailments is one of the pil-
lars of this recently adopted legislation. Due to health-
care professionals’ initiatives (pharmacists, doctors and
nurses), co-operation agreements (defined since July 21,
2009 by Article 4011-1 of the Public Health law) may be
signed, which follow the consultation with the Haute
Autorité de Santé (French National Authority for
Health) and authorization by the Agence Régionale de
Santé (Regional Health Agency). The objective is to
transfer activities and/or care and to reorganize inter-
vention procedures with patients between the different
health-care professionals according to their respective
knowledge and experience levels. In our study, the great
majority of young pharmacists look favorably on imple-
menting these measures. Nonetheless, according to our
respondents, lack of time and remuneration constitute
barriers for developing these new practices. In France
today, pharmacists are essentially remunerated through
profit margins on the medications they sell; therefore,
the present remuneration system would have to be
modified, and several alternatives can be envisaged. In
Quebec, pharmacists are moving towards a system of
being paid per pharmaceutical act [16]. In 2009, phar-
macist representatives in France proposed (in the Rap-
port Rioli [17]) a mixed system of remuneration, which
would make distinctions between the profit margins on
medications sold, the fees for pharmaceutical acts and
reimbursements for services provided. This proposal
was inspired by the 2005 agreement signed between the
National Health Service (NHS) and pharmacists [18] in
the United Kingdom. This agreement identifies three
levels of intervention, which differ according to the ser-
vices offered, the source of funding and the agreements
signed with the government. The Rapport Rioli also
considered the roles that the compulsory health
insurance system and complementary health plans
should play in providing these services. This agreement
was signed by eight pharmacist associations and was
approved by the Ministry of Health. There are already a
few initiatives wherein pharmacists are remunerated
independently of medication sales. The insurance com-
pany GMF-Allianz has developed a model contract that
remunerates pharmacists for their pharmaceutical con-
sultations [19]. La Mutuelle de la Région Lyonnaise
(complementary health plan of the Region of Lyon) is
proposing a personalized prevention assessment for
pharmacists. This assessment is made when a new con-
tract is signed, it is renewed every two years, and each
act is reimbursed up to a maximum of 22€ per benefi-
ciary. Thus, a debate regarding a new system of remu-
neration for pharmacists is taking place in France.
In our study, the lack of appropriate training was per-
ceived to represent a significant obstacle to developing
chronic disease management, particularly in the context
of increasing the coordinating role of pharmacists. In
2006, the World Health Organization and the Interna-
tional Pharmaceutical Federation (FIP) called for a new
paradigm in pharmaceutical care that would require
pharmacists to go beyond their training as experts in
chemistry and their knowledge of pharmaceutical pro-
ducts. This paradigm called on pharmacists to under-
stand and apply the principles involved in managing
medical therapies, such as the clinical and social roles of
pharmacies, communication, health promotion and
ethics [20,21]. The FIP also recommended increasing
vocational training for pharmacists [22]. In the United
Kingdom, for example, pharmacists can only provide
supplementary prescriptions after they train at a higher
education institution and complete a “period of learning
in practice” in accordance with the Royal Pharmaceuti-
cal Society of Great Britain curriculum. Currently, the
practice of clinical pharmacy is poorly developed in
France, in both hospitals and in the community. Starting
in the fall of 2010, a common first year may be estab-
lished for all students in medicine, pharmacy, dentistry
and midwifery, and this may become an opportunity to
create a common basis for these future health-care pro-
fessionals and encourage tomorrow’s collaborative
practices.
Pharmacies are providing more screening practices in
France, which are resulting from the combined initia-
tives of pharmacies collaborating with each other [23] or
during awareness campaigns such as “Diabetes Day.” In
light of what has been happening in Germany, pharma-
cies could offer their patients the possibility of monitor-
ing their blood pressure, blood-sugar levels, lipid values,
body mass index or waistline [24]. In addition to the
problems of remuneration and available working-time,
the principal obstacles mentioned by our respondents
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concerning these practices were pharmacy layout, lack
of space for meeting patients confidentially and compe-
tition with GPs, which is discussed below (see Phar-
macy-prescribed medication). Designated spaces in
pharmacies for respecting privacy or separate rooms for
these consultations have to be created to develop this
screening activity and to provide care for chronic ail-
ments. The Ordre des Pharmaciens (The College of
Pharmacists in France) mentioned this need in July 2006
[25]. Rapport et al. (2009) [26] were concerned with the
impact of the community pharmacy setting on profes-
sional practice and sense of self. They emphasized the
importance of separate enclosed consultation rooms in
pharmacies in the United Kingdom. Providing such
space would increase the degree of confidentiality dur-
ing consultations and heighten the professional’s sense
of being a valuable consultant and diagnostician.
However, typically, these spaces are not clearly reserved
for consultations, and they are often used for stocking
products due to the lack of space in small pharmacies.
Rapport et al. concluded that, unlike in the case of GPs,
a consultation room in a pharmacy tends to be a place
where the patient is encouraged to buy, be served and
move on instead of a place where the patient can expect
to spend time with a health-care professional.
Medication surveillance
For many years, strategies for using electronic health
records (e-hr) have been very different from one country
to another. One of the first uses of e-hr was for medical
prescriptions [27]. In France, an initial e-hr project Dos-
sier Médical Personnalisé was adopted into law on
August 13, 2004. It was abandoned due to problems
with its application, such as deadlines not being
respected and divergent interpretations of the limits and
uses of the e-hr. The purpose was to create an e-hr for
each person in France, which would include all of his or
her past and present medical information. The e-pr
developed independently of the e-hr. The e-pr is a phar-
macist’s professional tool designed to ensure the safe
dispensing of medications. It records all medications
delivered to a patient during the last four months from
every pharmacy, which are linked into the system. By
consulting the e-pr, the pharmacist can identify medic-
inal interactions and treatment redundancies. The
National Consultative Committee of the Ordre des Phar-
maciens, which initiated the e-pr, has been mandated by
law (n° 2007-127 of January 30, 2007) to use this system.
In the future, this will facilitate the implementation of
the e-hr program. In our study, the great majority of the
young pharmacists were open to creating these systems.
In 2010, nearly 10 million e-prs had already been cre-
ated in 18,000 pharmacies. However, obstacles to this
initiative have been identified, and patient reticence is
the most important. The patient has the right to refuse
the creation of their e-pr. This is consistent with results
of a recent study [28], which gathered the opinions of
patients, GPs and community pharmacists on the devel-
opment of an electronic transfer system for prescrip-
tion-related information between GPs and community
pharmacies. All groups acknowledged the potential ben-
efits of a full, primary-care information system, but GPs
and patients had reservations about allowing community
pharmacists to access parts of their medical records that
did not concern medications. Technical problems (such
as slow internet connections and lack of standardized
materials and software) and time were also cited as
major obstacles to developing the e-pr. Our respondents
also referred to other obstacles, such as patients opting
out of the e-pr and deciding on what data to include in
it. These obstacles and the technical issues contribute
greatly to the time constraints on e-pr development.
This would explain why, unlike with other practices, the
time constraint was not accompanied by the issue of
remuneration.
Pharmaceutical opinion is a procedure from Quebec.
In 1984, the Ordre des Pharmaciens du Québec defined
this as “a pharmacist’s judgment on the value of a med-
ication or medicinal treatment following his or her ana-
lysis of the patient’s e-pr “ [29]. Therefore, it is based
on the development of an e-pr. Since 1978, pharmacists
have been reimbursed for this development by the
Régie de l’Assurance-Maladie du Québec (Quebec pro-
vincial drug plan) [30]. In France, pharmacists often
contact prescribing doctors to revise a prescription
(regarding dosage, appropriateness, or errors), but there
are no formal procedures for transmitting such infor-
mation. These are considered telephone contacts and
are not billed by the pharmacist. This concept of phar-
maceutical opinion is nevertheless the subject of a
whole chapter in the French practical training guide for
final-year pharmacy students [31]. Moreover, in our
study, we found that respondents supported expanding
this procedure but reported that the practice of phar-
maceutical opinion faced major obstacles in terms of
the time this would require (independently of remu-
neration) and the technical problems. Kröger et al had
already discussed these obstacles in their 2000 study
that aimed to identify factors that influenced Quebec
community pharmacists to bill for a pharmaceutical
opinion or for a refusal to dispense. The typical phar-
macist who billed for opinions or refusals in Quebec
was < 45 years of age, had attended a continuing edu-
cation program on this topic and believed that billing
for interventions was important. He or she handled a
mean daily volume of 100-250 prescriptions, used a
decision-support computer program and had sufficient
technical staff assistance [32].
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Pharmacist-prescribed medication
One important finding in our research was that our
respondents wanted to increase their status as pharma-
cist-prescribers for minor ailments (82.6%) but not to
increase their sales of OTC drugs (34.3%). This reflects
the recent debate in France over selling medications in
supermarkets [33]. The majority of tomorrow’s pharma-
cists think that pharmacies are not drugstores. This is
consistent with the position of the professional associa-
tion in defending its monopoly. France is one of the last
European countries along with Spain, Italy and Greece
where pharmacies have a monopoly over all medications
(the sale and distribution of all medications whether or
not they require a prescription) [34]. In our study, the
problem of competing with doctors for pharmacy-
prescribed medications echoes the debate over the
recognition of pharmacists prescribing for minor ail-
ments. Thus, even if the official representatives of the
profession are ready to implement this, a survey
reported in 2005 in the Quotidien du médecin showed
that 6 out of 10 GPs were still opposed to pharmacists
prescribing for low-risk ailments [35]. Since 2005, phar-
macists have been authorized to dispense medications
for contraception and for breaking tobacco addiction.
Participation in health-care networks
The practice of direct collaborations between pharma-
cists and other health-care professionals (particularly
GPs) to discuss a patient’s clinical case has been bor-
rowed from the “pharmacotherapeutic consultation
groups” (FTOs) in the Netherlands [8], where these col-
laborations began in the 1990s to improve co-ordination
between health professionals. In France, such practices
appear to occur infrequently, but they are, nevertheless,
developing through the extension of health-care net-
works and the increased participation of pharmacists in
these networks [36]. Time and remuneration, according
to our respondents, were the principal obstacles to
developing this practice.
Limitations
This study has several limitations. First, the respondents
were young Parisian pharmacy students, and their opi-
nions may not reflect those of pharmacists throughout
France, given the urban setting of their practices; how-
ever, even if Paris is not one of the areas most exposed
to problems of proximity and access to health care, the
respondents were in favor of (or strongly in favor of) to
developing the new practices included in our study. Sec-
ond, the results of this opinion survey would have been
very different, particularly with respect to the obstacles
to developing new practices, if the respondents had
already been established pharmacists. Our choice of
final-year pharmacy students, in addition to the fact that
they were accessible, was justified because all respon-
dents would soon be affected by the current reform.
Third, this is a study of opinions from the pharmacist’s
perspective, and the results cannot be seen as predictors
of the adoption and application of the reform. They
have to be considered alongside the opinions of the two
other major protagonists: doctors and patients. This
merits subsequent research.
Conclusions
Overall, the final-year pharmacy students participating in
this study, who are tomorrow’s pharmacists, held favorable
opinions toward developing new practices that are more
focused on the patient. However, they saw many obstacles
for themselves in the diffusion of these practices. The
most significant obstacles were remuneration, working
time and organizational and technical problems. The
Ordre des Pharmaciens has proposed solutions to these
problems based on the experiences of other countries.
However, nothing can be achieved without creating coop-
eration contracts with other health-care professionals, par-
ticularly doctors, to provide care for chronic ailments. The
patient’s consent must also be obtained. The opinions of
doctors and patients remain as open questions.
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